Table 2

Distribution of comorbidities and their associations with different factors

No of comorbiditiesNo (%)SexAge (Years)
Male (%)Female (%)0-3 (%)4-7 (%)8-18 (%)
No comorbidities30 (0.74)20 (66.67)10 (33.33)6 (20.00)13 (43.33)11 (36.67)
One comorbidity2709 (66.97)1833 (67.66)876 (32.34)814 (30.05)1591 (58.73)304 (11.22)
 Top five patterns of one comorbidity:
  OSAHS +chronic rhinitis1518 (37.53)1025 (67.52)493 (32.48)442 (29.12)905 (59.62)171 (11.26)
  OSAHS +allergic rhinitis1138 (28.13)770 (67.66)368 (32.34)359 (31.55)655 (57.56)124 (10.90)
  OSAHS +chronic tonsillitis15 (0.37)8 (53.33)7 (46.67)2 (13.33)7 (46.67)6 (40.00)
  OSAHS +adenoidal hypertrophy14 (0.35)11 (78.57)3 (21.43)3 (21.43)9 (64.29)2 (14.29)
  OSAHS +chronic sinusitis8 (0.20)5 (62.50)3 (37.50)2 (25.00)6 (75.00)0 (00.00)
  P value0.6880.035
Two comorbidities1210 (29.91)817 (67.52)393 (32.48)363 (30.00)748 (61.82)99 (8.18)
 Top five patterns of two comorbidities:
  OSAHS +chronic rhinitis +chronic exudative otitis media440 (10.88)292 (66.36)148 (33.64)173 (39.32)247 (56.14)20 (4.55)
  OSAHS +allergic rhinitis +chronic exudative otitis media321 (7.94)218 (67.91)103 (32.09)113 (35.20)196 (61.06)12 (3.74)
  OSAHS +allergic rhinitis +chronic tonsillitis179 (4.43)112 (62.57)67 (37.43)32 (17.88)122 (68.16)25 (13.97)
  OSAHS +chronic rhinitis +chronic tonsillitis171 (4.23)124 (72.51)47 (27.49)28 (16.37)122 (71.35)21 (12.28)
  OSAHS +adenoidal hypertrophy +tonsil hypertrophy19 (0.47)15 (78.95)4 (21.05)1 (5.26)12 (63.16)6 (31.58)
  P value0.254<0.001
≥3 comorbidities*96 (2.37)62 (64.58)34 (35.42)30 (31.25)61 (63.54)5 (5.21)
No of comorbiditiesNo of admissionsNo of operationsLOS
1 (%)≥2 (%)0 (%)1 (%)≥2 (%)Median (IQR)
No comorbidities26 (86.67)4 (13.33)12 (40.00)18 (60.00)0 (00.00)2.00 (1.00–2.00)
One comorbidity2416 (89.18)293 (10.82)38 (1.40)2640 (97.45)31 (1.14)2.00 (2.00–2.00)
 Top five patterns of one comorbidity:
  OSAHS +chronic rhinitis1356 (89.33)162 (10.67)16 (1.05)1492 (98.29)10 (0.66)2.00 (2.00–2.00)
  OSAHS +allergic rhinitis1013 (89.02)125 (10.98)12 (1.05)1119 (98.33)7 (0.62)2.00 (2.00–2.00)
  OSAHS +chronic tonsillitis11 (73.33)4 (26.67)1 (6.67)14 (93.33)0 (0.00)2.00 (2.00–3.00)
  OSAHS +adenoidal hypertrophy13 (92.86)1 (7.14)8 (57.14)1 (7.14)5 (35.71)1.00 (1.00–3.00)
  OSAHS +chronic sinusitis8 (100.00)0 (00.00)1 (12.50)7 (87.50)0 (0.00)2.00 (1.00–3.00)
  P value0.275<0.0010.491
Two comorbidities1089 (90.00)121 (10.00)24 (1.98)628 (51.90)558 (46.12)2.00 (2.00–2.00)
 Top five patterns of two comorbidities:
  OSAHS +chronic rhinitis +chronic exudative otitis media393 (89.32)47 (10.68)8 (1.82)167 (37.95)265 (60.23)2.00 (2.00–3.00)
  OSAHS +allergic rhinitis +chronic exudative otitis media292 (90.97)29 (9.03)1 (0.31)74 (23.05)246 (76.64)2.00 (2.00–2.00)
  OSAHS +allergic rhinitis +chronic tonsillitis166 (92.74)13 (7.26)2 (1.12)176 (98.32)1 (0.56)2.00 (2.00–2.00)
  OSAHS +chronic rhinitis +chronic tonsillitis146 (85.38)25 (14.62)2 (1.17)166 (97.08)3 (1.75)2.00 (2.00–2.00)
  OSAHS +adenoidal hypertrophy +tonsil hypertrophy18 (94.74)1 (5.26)1 (5.26)9 (47.37)9 (47.37)4.00 (3.00–4.00)
  P value0.169<0.001<0.001
≥3 comorbidities*81 (84.38)15 (15.63)4 (4.17)21 (21.88)71 (73.96)2.00 (2.00–3.00)
  • The p values in table 2 were used to reflect the differences in the top five patterns within the one comorbidity group and two comorbidities group.

  • *The subgroups of ≥3 comorbidities are not shown in this table since the frequency distribution was uniform and comorbidities varied greatly.

  • LOS, length of stay; OSAHS, obstructive sleep apnoea–hypopnoea syndrome.